These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30363472)

  • 41. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
    Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
    J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
    Meles SK; Oertel WH; Leenders KL
    Mol Med; 2021 Sep; 27(1):111. PubMed ID: 34530732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracellular Vesicles in the Treatment of Parkinson's Disease: A Review.
    Yang X; Ma Y; Xie H; Dong S; Rao G; Yang Z; Zhang J; Wu Q
    Curr Med Chem; 2021; 28(31):6375-6394. PubMed ID: 33441061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.
    Dixit A; Mehta R; Singh AK
    Cell Mol Neurobiol; 2019 Oct; 39(7):901-915. PubMed ID: 31190159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid biomarker for Parkinson's disease: An overview.
    Maass F; Schulz I; Lingor P; Mollenhauer B; Bähr M
    Mol Cell Neurosci; 2019 Jun; 97():60-66. PubMed ID: 30543858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A systems biology approach towards the identification of candidate therapeutic genes and potential biomarkers for Parkinson's disease.
    Sakharkar MK; Kashmir Singh SK; Rajamanickam K; Mohamed Essa M; Yang J; Chidambaram SB
    PLoS One; 2019; 14(9):e0220995. PubMed ID: 31487305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarkers for Parkinson's Disease: How Good Are They?
    Li T; Le W
    Neurosci Bull; 2020 Feb; 36(2):183-194. PubMed ID: 31646434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson's Disease.
    Zardini Buzatto A; Tatlay J; Bajwa B; Mung D; Camicioli R; Dixon RA; Li L
    J Proteome Res; 2021 Aug; 20(8):4053-4067. PubMed ID: 34251208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.
    Lee SH; Park SM; Yeo SS; Kwon O; Lee MK; Yoo H; Ahn EK; Jang JY; Jang JH
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New markers in Parkinson's disease.
    Bougea A
    Adv Clin Chem; 2020; 96():137-178. PubMed ID: 32362317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mass spectrometry for the detection of potential psychiatric biomarkers.
    Ngounou Wetie AG; Sokolowska I; Wormwood K; Beglinger K; Michel TM; Thome J; Darie CC; Woods AG
    J Mol Psychiatry; 2013; 1(1):8. PubMed ID: 25408901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers.
    Anjo SI; Dos Santos PV; Rosado L; Baltazar G; Baldeiras I; Pires D; Gomes A; Januário C; Castelo-Branco M; Grãos M; Manadas B
    Transl Neurodegener; 2020; 9():11. PubMed ID: 32266064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?
    Le W; Dong J; Li S; Korczyn AD
    Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Systematic Review of Neurofeedback for the Management of Motor Symptoms in Parkinson's Disease.
    Anil K; Hall SD; Demain S; Freeman JA; Ganis G; Marsden J
    Brain Sci; 2021 Sep; 11(10):. PubMed ID: 34679358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Application of Circulating MicroRNAs in Parkinson's Disease: The Challenges and Opportunities as Diagnostic Biomarker.
    Ramaswamy P; Yadav R; Pal PK; Christopher R
    Ann Indian Acad Neurol; 2020; 23(1):84-97. PubMed ID: 32055127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.